Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles

被引:12
|
作者
Balayla, Jacques [1 ]
Tulandi, Togas [1 ]
Buckett, William [1 ]
Holzer, Hananel [1 ,2 ]
Steiner, Naama [1 ]
Shrem, Guy [1 ]
Volodarsky-Perel, Alexander [1 ,3 ]
机构
[1] McGill Univ, Dept Obstet & Gynecol, 1001 Decarie Blvd, Montreal, PQ H4A 3J1, Canada
[2] Hadassah Med Ctr, Dept Obstet & Gynecol, IL-91120 Jerusalem, Israel
[3] Jewish Gen Hosp, Lady Davis Res Inst, 3755 Chemin Cote St Catherine, Montreal, PQ H3T 1E2, Canada
关键词
Triple-negative breast cancer; Fertility preservation; Number of oocytes; Estrogen receptor; Progesterone receptor; EMBRYO-TRANSFER; LIVE BIRTH; WOMEN; ESTROGEN; TAMOXIFEN; ASSOCIATION; EXPRESSION; MUTATIONS; FEATURES; IMPACT;
D O I
10.1007/s10815-020-01730-9
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Purpose To evaluate fertility preservation outcomes in breast cancer women with different hormonal receptor profiles before oncological treatment. Methods The study population included women with a diagnosis of breast cancer who underwent fertility preservation from 2009 until 2018 at a university-affiliated tertiary hospital. Stimulation parameters and fertility preservation outcomes were compared among the following receptor-specific profile groups: (1) estrogen receptor positive (ER+) versus estrogen receptor negative (ER-), (2) triple-negative breast cancer (TNBC) versus estrogen and progesterone receptor positive (ER+/PR+), and (3) TNBC versus non-TNBC. Primary outcome was the total number of mature oocytes. Secondary outcomes included the number of retrieved oocytes, the peak estradiol level, and the number of follicles > 14 mm on the final oocyte maturation trigger day. Results A total of 155 cycles were included in the final analysis. These were divided into the exposure groups of ER+ (n = 97), ER- (n = 58), ER+/PR+ (n = 85), TNBC (n = 57), and non-TNBC (n = 98). Cycle outcomes revealed similar number of retrieved oocytes and follicles > 14 mm on the trigger day. Women with TNBC had significantly lower number of mature oocytes compared with those with ER + PR+ (7 (5-11) versus 9 (7-15); p = 0.02) and non-TNBC (7 (5-11) versus 9 (7-16); p = 0.01) status. Triple-negative breast cancer profile was associated with a significant reduction in the chance of developing over 10 mature oocytes (OR 0.41; 95% CI 0.19-0.92). Conclusion Among the different hormonal receptor profiles in breast cancer, the TNBC subtype has a negative effect on fertility preservation outcomes.
引用
收藏
页码:913 / 921
页数:9
相关论文
共 50 条
  • [1] Outcomes of ovarian stimulation and fertility preservation in breast cancer patients with different hormonal receptor profiles
    Jacques Balayla
    Togas Tulandi
    William Buckett
    Hananel Holzer
    Naama Steiner
    Guy Shrem
    Alexander Volodarsky-Perel
    Journal of Assisted Reproduction and Genetics, 2020, 37 : 913 - 921
  • [2] Ovarian stimulation response and fertility outcomes in patients with breast cancer across different stages, grades, and hormone receptor status for fertility preservation
    Liu, Shang-Min
    Huang, Shang-Yu
    Wu, Hsien-Ming
    Chang, Chia-Lin
    Huang, Hong-Yuan
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2025, 124 (03) : 241 - 245
  • [3] Impact of fertility preservation by ovarian stimulation on breast cancer outcomes.
    Wang, Ying
    Lee, Shaina
    Camateros, Pierre
    Perdrizet, Kirstin Ann
    Yokom, Daniel
    Warner, Ellen
    Roberts, Jeffrey
    Lohrisch, Caroline A.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] A NOVEL PROTOCOL OF OVARIAN STIMULATION FOR FERTILITY PRESERVATION IN BREAST CANCER PATIENTS
    Cavagna, M.
    Dzik, A.
    Donadio, N. F.
    Freitas, G. C.
    Cavagna, F.
    Gebrim, L. H.
    FERTILITY AND STERILITY, 2012, 98 (03) : S120 - S121
  • [5] Ovarian stimulation for fertility preservation in patients with cancer
    Quintero, Rudolpho B.
    Helmer, Amy
    Huang, Jian Qun
    Westphal, Lynn M.
    FERTILITY AND STERILITY, 2010, 93 (03) : 865 - 868
  • [6] Ovarian stimulation and PGT-A outcomes with random start letrozole protocol for fertility preservation in breast cancer patients
    Arkfeld, C.
    Gayete-Lafuente, S.
    Turan, V.
    Oktay, K.
    HUMAN REPRODUCTION, 2022, 37 : I417 - I417
  • [7] Impact of letrozole supplementation during ovarian stimulation for fertility preservation in breast cancer patients
    Sonigo, Charlotte
    Sermondade, Nathalie
    Calvo, Jeremy
    Benard, Julie
    Sifer, Christophe
    Grynberga, Michael
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY-X, 2019, 4
  • [8] Sleep Disturbance and Ovarian Stimulation Outcomes in Infertility and Fertility Preservation Patients
    Lyttle, Brianna M. W.
    Lawson, Angela K.
    Klock, Susan
    Smith, Kristin
    Kazer, Ralph
    Hirshfeld-Cytron, Jennifer
    Pavone, Mary Ellen
    JOURNAL OF REPRODUCTIVE MEDICINE, 2018, 63 (5-6) : 292 - 298
  • [9] Impact of ovarian stimulation for fertility preservation in young women with breast cancer: Updated survival and pregnancy outcomes
    Tesch, Megan E.
    Wang, Ying
    Lim, Chloe
    Xu, Ying Hui
    Lee, Shaina
    Perdrizet, Kirstin
    Yokom, Dan
    Warner, Ellen
    Roberts, Jeffrey
    Lohrisch, Caroline
    CANCER RESEARCH, 2022, 82 (04)
  • [10] Progesterone levels in letrozole associated controlled ovarian stimulation for fertility preservation in breast cancer patients
    Goldrat, O.
    Gervy, C.
    Englert, Y.
    Delbaere, A.
    Demeestere, I.
    HUMAN REPRODUCTION, 2015, 30 (09) : 2184 - 2189